Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
Date:3/8/2010

GAAP net income -continuing operations 12,511 (49,239) * 53,432 (14,951) * GAAP net margin -continuing operations 17% (76%) 20% (6%) Adjustments: Share-based compensation 2,972 3,521 10,220 13,046 Amortization of acquired intangible assets 764 3,896 3,057 11,175 Impairment charge 60,497 60,497 Deferred tax impact related to acquired intangible assets (296) (8,648) (1,184) (11,502) Non-GAAP net income 15,951 10,027 59% 65,525 58,265 12% Non-GAAP net margin 22% 16% 24% 23% GAAP net income 12,127 (93,851) * 52,874 (64,203) * Add back: Depreciation and amorti- zation 6,726 6,264 23,974 30,587 Interest (income) expenses, net (102) (270) (57) (913) Income tax expenses (benefit) 478 (15,283) 5,143 (16,429) EBITDA 19,229 (103,140) * 81,934 (50,958) * Adjustments: Share-based compensation 2,972 3,521 10,220 13,046 Mark-to-market 1,226 626 (481) 2,758 losses (gains) on foreign- exchange forward contracts Impairment charge -continuing operations 60,497 60,497 Impairment charge-dis- continued operations 591 49,581 591 49,581 Adjusted EBITDA 24,018 11,085 * 92,264 74,924 23% Income attri- butable to holders of ADS (
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
2. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
3. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
4. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
5. WuXi PharmaTech Announces Second-Quarter 2009 Results
6. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
7. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
8. WuXi PharmaTech Receives Award from BASF
9. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
10. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
11. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Microdosing or Phase 0 clinical testing has ... phase of the drug development process in the ... providers in preclinical testing and technology dependence is ... alliances, fuelling growth opportunities in this sector.(Logo: ...
... BASEL, Switzerland, Feb. 10 Syngenta today announced that ... Rice Research Institute (ARRI) of Anhui Academy of Agricultural ... conducting laboratory and field tests of novel gene functions ... optimization in key crops such as corn and soybean. ...
... CHAMPAIGN, Ill. By pushing carbon nanotubes close ... of Illinois have demonstrated a remarkable increase in ... what was previously thought possible., The researchers drove ... carries more electrons down more paths, similar to ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 3Syngenta Enters Into Research Collaboration With Anhui Academy, China 2Syngenta Enters Into Research Collaboration With Anhui Academy, China 3Carbon nanotube avalanche process nearly doubles current 2
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... A new study has identified two factors that ... increase the production of highly qualified physics teachers. ... to champion physics teacher education in combination with ... initiatives remain viable. Science, Technology, Engineering and Math ... and the study points the way for institutions ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Creating sustainable STEM teacher preparation programs 2
... Department of Cell Biology and Histology at the University of ... boosted by means of retinoids. It was thought that this ... , Vitamin A, also known as retinol, is ... and as carotene in vegetables that have a yellow-orange colour, ...
... identified a compound that interferes with the pathogenic effects ... development of a new treatment for the disease. , ... that now afflicts 30,000 Americans, with another 150,000 at ... strikes in midlife and causes uncontrolled movements, loss of ...
... Dentistry professor has developed a calcium phosphate-based supplement that ... strength and thickness without the side effects of many ... of Biomaterials and Biomimetics and of Implant Dentistry, presented ... for Dental Research annual meeting on March 9, 2006. ...
Cached Biology News:Retinol for combating leukemia cells 2Retinol for combating leukemia cells 3MIT research holds promise for Huntington's treatment 2New study reveals promising osteoporosis treatment 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... is an enhanced form of Tobacco Etch ... highly active, and significantly more stable than ... AcTEV Protease specifically recognizes a seven amino ... making it useful for removing affinity tags ...
... The Heraeus HERAcell is the ideal ... including development of ova or embryos at ... specifically designed to provide everything needed to ... , , Safe and stable incubation conditions ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
Biology Products: